Literature DB >> 21031218

An androgenic steroid delivery vector that imparts activity to a non-conventional platinum(II) metallo-drug.

Martin Huxley1, Carlos Sanchez-Cano, Michael J Browning, Carmen Navarro-Ranninger, Adoracion G Quiroga, Alison Rodger, Michael J Hannon.   

Abstract

A range of androgen conjugates with non-conventional platinum(II) complexes have been synthesised with the aim of targeting tumour cells since many display elevated levels of the androgen receptor. The androgenic platinum conjugates are delivered into selected cells with improved efficiency (when compared to their non-steroidal analogues). The act of conjugating an androgen to a platinum(II) complex resulted in synergistic effects between the metallic centre and the steroidal ligand, creating highly potent platinum(II) complexes from the inactive components.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21031218     DOI： 10.1039/c0dt00838a

Source DB:  PubMed          Journal:  Dalton Trans        ISSN： 1477-9226            Impact factor:   4.390


  10 in total

1.  Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile.

Authors:  Ga Young Park; Justin J Wilson; Ying Song; Stephen J Lippard
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-06       Impact factor: 11.205

Review 2.  Synthetic methods for the preparation of platinum anticancer complexes.

Authors:  Justin J Wilson; Stephen J Lippard
Journal:  Chem Rev       Date:  2013-11-27       Impact factor: 60.622

3.  Monofunctional and higher-valent platinum anticancer agents.

Authors:  Timothy C Johnstone; Justin J Wilson; Stephen J Lippard
Journal:  Inorg Chem       Date:  2013-06-05       Impact factor: 5.165

4.  Anticancer activity, DNA binding and cell mechanistic studies of estrogen-functionalised Cu(II) complexes.

Authors:  Stephen Barrett; Michele De Franco; Andrew Kellett; Eithne Dempsey; Cristina Marzano; Andrea Erxleben; Valentina Gandin; Diego Montagner
Journal:  J Biol Inorg Chem       Date:  2019-10-26       Impact factor: 3.358

Review 5.  Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistance.

Authors:  Xiaohong Tian; Yang He; Jinming Zhou
Journal:  Front Pharmacol       Date:  2015-03-24       Impact factor: 5.810

Review 6.  Androgen Receptor-Directed Molecular Conjugates for Targeting Prostate Cancer.

Authors:  Giovanni L Beretta; Nadia Zaffaroni
Journal:  Front Chem       Date:  2019-05-28       Impact factor: 5.221

Review 7.  Eighty Years of Targeting Androgen Receptor Activity in Prostate Cancer: The Fight Goes on.

Authors:  Eva Estébanez-Perpiñá; Charlotte L Bevan; Iain J McEwan
Journal:  Cancers (Basel)       Date:  2021-01-29       Impact factor: 6.639

8.  Disturbance of DNA conformation by the binding of testosterone-based platinum drugs via groove-face and intercalative interactions: a molecular dynamics simulation study.

Authors:  Shanshan Cui; Yan Wang; Guangju Chen
Journal:  BMC Struct Biol       Date:  2013-03-22

Review 9.  Targeting the androgen receptor with steroid conjugates.

Authors:  Paul M Levine; Michael J Garabedian; Kent Kirshenbaum
Journal:  J Med Chem       Date:  2014-07-08       Impact factor: 7.446

Review 10.  A sting in the tail: the N-terminal domain of the androgen receptor as a drug target.

Authors:  Amy E Monaghan; Iain J McEwan
Journal:  Asian J Androl       Date:  2016 Sep-Oct       Impact factor: 3.285
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.